Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Wassmer, Sarah J ^a,b,c   Carvalho, Livia S ^a,b,c   György, Bence ^c,d   Vandenberghe, Luk H ^a,b,c   Maguire, Casey A ^c  

^a HARVARD STEM CELL INSTITUTE   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; EXOSOME; GENE TRANSFER; GENE VECTOR; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; RETINA;

ANIMALS; DEPENDOVIRUS; EXOSOMES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; INTRAVITREAL INJECTIONS; MALE; MICE; RETINA;

EID: 85016767902     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45329     Document Type: Article

References (45)

1. Maguire, A. M. et al. Safety and efcacy of gene transfer for Leber's congenital amaurosis. The New England journal of medicine 358, 2240-2248, doi: 10.1056/NEJMoa0802315 (2008).
2. Bainbridge, J. W. et al. Efect of gene therapy on visual function in Leber's congenital amaurosis. The New England journal of medicine 358, 2231-2239, doi: 10.1056/NEJMoa0802268 (2008).
3. Cideciyan, A. V. et al. Human gene therapy for RPE65 isomerase defciency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences of the United States of America 105, 15112-15117, doi: 10.1073/pnas.0807027105 (2008).
4. Jacobson, S. G. et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Human gene therapy 17, 845-858, doi: 10.1089/hum.2006.17.845 (2006).
5. Maguire, A. M. et al. Age-dependent efects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597-1605, doi: 10.1016/S0140-6736(09)61836-5 (2009).
6. Park, S. W., Kim, J. H., Park, W. J. & Kim, J. H. Limbal Approach-Subretinal Injection of Viral Vectors for Gene Terapy in Mice Retinal Pigment Epithelium. Journal of visualized experiments: JoVE e53030, doi: 10.3791/53030 (2015).
7. Vacca, O. et al. Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease. Journal of visualized experiments: JoVE doi: 10.3791/52451 (2015).
8. Petrs-Silva, H. et al. High-efciency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Molecular therapy: the journal of the American Society of Gene Terapy 17, 463-471, doi: 10.1038/mt.2008.269 (2009).
9. Tshilenge, K. T. et al. Vitrectomy Before Intravitreal Injection of AAV2/2 Vector Promotes Efficient Transduction of Retinal Ganglion Cells in Dogs and Nonhuman Primates. Human gene therapy methods 27, 122-134, doi: 10.1089/hgtb.2016.034 (2016).
10. Cehajic-Kapetanovic, J., Le Gof, M. M., Allen, A., Lucas, R. J. & Bishop, P. N. Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2. Molecular vision 17, 1771-1783 (2011).
11. Dalkara, D. et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Molecular therapy: the journal of the American Society of Gene Terapy 17, 2096-2102, doi: 10.1038/mt.2009.181 (2009).
12. Gyorgy, B., Hung, M. E., Breakefeld, X. O. & Leonard, J. N. Terapeutic applications of extracellular vesicles: clinical promise and open questions. Annual review of pharmacology and toxicology 55, 439-464, doi: 10.1146/annurev-pharmtox-010814-124630 (2015).
13. Gyorgy, B. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cellular and molecular life sciences: CMLS 68, 2667-2688, doi: 10.1007/s00018-011-0689-3 (2011).
14. Maguire, C. A. et al. Microvesicle-associated AAV vector as a novel gene delivery system. Molecular therapy: the journal of the American Society of Gene Terapy 20, 960-971, doi: 10.1038/mt.2011.303 (2012).
15. Gyorgy, B., Fitzpatrick, Z., Crommentuijn, M. H., Mu, D. & Maguire, C. A. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials 35, 7598-7609, doi: 10.1016/j.biomaterials.2014.05.032 (2014).
16. Hudry, E. et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene therapy 23, 380-392, doi: 10.1038/gt.2016.11 (2016).
17. El Andaloussi, S., Lakhal, S., Mager, I. & Wood, M. J. Exosomes for targeted siRNA delivery across biological barriers. Advanced drug delivery reviews 65, 391-397, doi: 10.1016/j.addr.2012.08.008 (2013).
18. Yang, T. et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharmaceutical research 32, 2003-2014, doi: 10.1007/s11095-014-1593-y (2015).
19. De Silva, S. R. et al. Single residue AAV capsid mutation improves trans duction of photoreceptors in the Ab ca4-/-mouse and bipolar cells in the rd1 mouse and human retina ex vivo. Gene therapy, doi: 10.1038/gt.2016.54 (2016).
20. Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108-112, doi: 10.1038/nature16465 (2016).
21. Woodard, K. T., Liang, K. J., Bennett, W. C. & Samulski, R. J. Heparan Sulfate Binding Promotes Accumulation of Intravitreally-Delivered Adeno-Associated Viral Vectors at the Retina for Enhanced Transduction but Weakly Influences Tropism. Journal of virology, doi: 10.1128/JVI.01568-16 (2016).
22. Balaj, L. et al. Heparin afnity purifcation of extracellular vesicles. Scientifc reports 5, 10266, doi: 10.1038/srep10266 (2015).
23. Atai, N. A. et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of neuro-oncology 115, 343-351, doi: 10.1007/s11060-013-1235-y (2013).
24. Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J. P. & Belting, M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proceedings of the National Academy of Sciences of the United States of America 110, 17380-17385, doi: 10.1073/pnas.1304266110 (2013).
25. Vacca, O. et al. AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. Glia 62, 468-476, doi: 10.1002/glia.22617 (2014).
26. Spiteri Cornish, K. et al. Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole. Ophthalmology 121, 649-655, doi: 10.1016/j.ophtha.2013.10.020 (2014).
27. Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Science translational medicine 5, 189ra176, doi: 10.1126/scitranslmed.3005708 (2013).
28. Ramachandran, P. S. et al. Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. Human gene therapy, doi: 10.1089/hum.2016.111 (2016).
29. Petrs-Silva, H. et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Molecular therapy: the journal of the American Society of Gene Terapy 19, 293-301, doi: 10.1038/mt.2010.234 (2011).
30. Mowat, F. M. et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene therapy 21, 96-105, doi: 10.1038/gt.2013.64 (2014).
31. Kay, C. N. et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PloS one 8, e62097, doi: 10.1371/journal.pone.0062097 (2013).
32. Vandenberghe, L. H. & Auricchio, A. Novel adeno-associated viral vectors for retinal gene therapy. Gene therapy 19, 162-168, doi: 10.1038/gt.2011.151 (2012).
33. Boyd, R. F. et al. Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs. Gene therapy 23, 400, doi: 10.1038/gt.2016.10 (2016).
34. Giove, T. J., Sena-Esteves, M. & Eldred, W. D. Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection. Experimental eye research 91, 652-659, doi: 10.1016/j.exer.2010.08.011 (2010).
35. Wiley, R. D. & Gummuluru, S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proceedings of the National Academy of Sciences of the United States of America 103, 738-743, doi: 10.1073/pnas.0507995103 (2006).
36. Feng, Z. et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496, 367-371, doi: 10.1038/nature12029 (2013).
37. Yang, Y. et al. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cellular & molecular immunology, doi: 10.1038/cmi.2016.24 (2016).
38. Ran, L. et al. Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy. Biomaterials 89, 56-66, doi: 10.1016/j.biomaterials.2016.02.025 (2016).
39. Dudus, L. et al. Persistent transgene product in retina, optic nerve and brain afer intraocular injection of rAAV. Vision research 39, 2545-2553 (1999).
40. Mulcahy, L. A., Pink, R. C. & Carter, D. R. Routes and mechanisms of extracellular vesicle uptake. Journal of extracellular vesicles 3, doi: 10.3402/jev.v3.24641 (2014).
41. Da Costa, R. et al. A Novel Method Combining Vitreous Aspiration and Intravitreal AAV2/8 Injection Results in Retina-Wide Transduction in Adult Mice. Investigative ophthalmology & visual science 57, 5326-5334, doi: 10.1167/iovs.16-19701 (2016).
42. Boye, S. L. et al. Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors. Journal of virology 90, 4215-4231, doi: 10.1128/JVI.00200-16 (2016).
43. Kwong, J. M., Caprioli, J. & Piri, N. RNA binding protein with multiple splicing: a new marker for retinal ganglion cells. Investigative ophthalmology & visual science 51, 1052-1058, doi: 10.1167/iovs.09-4098 (2010).
44. Wassle, H., Yamashita, M., Greferath, U., Grunert, U. & Muller, F. The rod bipolar cell of the mammalian retina. Visual neuroscience 7, 99-112 (1991).
45. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nature methods 9, 671-675 (2012).